Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.64 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.64 |
| ▸ | HTR3B | O95264 | 4/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080727 | 1.00 | HTR3A (0.64) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL19385628 | 0.98 | HTR3A (0.62) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL651717 | 0.86 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Octane SCHEMBL7483050 | 0.85 | HTR3E (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL30609685 | 0.84 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL6531534 | 0.84 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL3342489 | 0.84 | PLD1 (0.62) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL5577769 | 0.84 | HTR3E (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL14013835 | 0.83 | ALDH1A1 (0.67) | NPSR1ALDH1A1MEN1KMT2AMCOLN3 | |
| SCHEMBL4328782 | 0.81 | ADRB1 (0.63) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074839-A | Composition and method for treating the metabolism illness related to body weight | 贝勒医学院 | 2017-08-18 | — | — | CN | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12202811-B2 | Compounds for treating prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2024-05-23 | — | — | US | disclosed |
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| EP-1100794-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN $g(a) 1d? ADRENERGIC RECEPTOR AND USES THEREOF | Synaptic Pharmaceutical Corporation (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| WO-2001005765-A1 | CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000004012-A9 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| WO-2000004012-A1 | COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-01-27 | — | — | WO | disclosed |
| US-5780472-A | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAZL CO., LTD. (KR) | 1998-07-14 | — | — | US | disclosed |
| EP-0749425-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARM. CO., LTD. (KR) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996021648-A1 | NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1996-07-18 | — | — | WO | disclosed |
| US-5110816-A | Urogenital disorders | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (I.R.C.E.B.A.) (FR) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905268-B2 | Anthranilic acid derivatives and their use in the treatment of human cancers | ANXA6, ANXA1, ANTXR2 | HTR3A 2070/4885HTR3E 2854/4885HTR3B 3231/4885 |
| US-12202811-B2 | Compounds for treating prostate cancer | AR, HDAC10, NR5A1 | HTR3A 1708/4885HTR3E 2405/4885HTR3B 2088/4885 |
| US-12365659-B2 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | SLC19A1, PNMT, SRM | HTR3A 1062/4885HTR3E 1563/4885HTR3B 1312/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | HTR3A 1968/4885HTR3E 2477/4885HTR3B 1917/4885 |
| US-20240166614-A1 | NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERS | SLC19A1, PNMT, SRM | HTR3A 1062/4885HTR3E 1563/4885HTR3B 1312/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HTR3A 2316/4885HTR3E 2151/4885HTR3B 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.